• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers

Cardio3 BioSciences Announces Results of Annual Shareholder Assembly 2015 and Confirmation of Name Change to Celyad

May 5, 2015 By Celyad

2014 Annual Report now available on new website www.celyad.com

Mont-Saint-Guibert, Belgium – Cardio3 BioSciences (“the Company”) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of engineered cell therapies, today announced that all resolutions presented at the Company’s Annual Shareholder Assembly were duly passed at the meeting, which was held today at 09:00 CET.

As a result, the Company’s proposed name change to “Celyad” is now confirmed, effective immediately. The new corporate website is available online at www.celyad.com. Furthermore, as of 09:00 CET on 6 May 2015, the Company will trade on the Euronext Brussels and Paris regulated markets under the symbol CYAD, replacing former symbol CARD. No specific action is required from our shareholders following this symbol change.

The Company is also pleased to announce that copies of the 2014 Annual Report and Accounts will be made available to shareholders on the “Investors” section of the Company’s website at www.celyad.com, and paper copies will be made available upon request to the Company.

To read the NL version, please click here

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Corporate, Regulated

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy